Ana Corrêa-Nunes

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
The use of biomarkers within the procedures of the Committee of Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) is discussed herein. The applications for Orphan Medicinal Product designation in the EU are evaluated at two stages. At the time of orphan designation application, the file undergoes an assessment to establish whether the(More)
  • 1